Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for multiple myeloma.

S Vincent Rajkumar1, Morie A Gertz, Robert A Kyle

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA. rajks@mayo.edu

Mayo Clinic Proceedings
|August 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How I treat cold agglutinin hemolytic anemia.

Clinical advances in hematology & oncology : H&O·2019
Same author

Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Brain and behavior·2019
Same author

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2019
Same author

Therapy of Transthyretin Cardiomyopathy.

Journal of the American College of Cardiology·2019
Same author

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Acta haematologica·2019
Same author

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

British journal of haematology·2019
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Recent advances in multiple myeloma treatment, including stem cell transplantation and novel agents like thalidomide, have significantly improved patient survival beyond traditional melphalan and prednisone therapy.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma is an incurable plasma cell malignancy, historically treated with melphalan and prednisone, yielding a median survival of approximately 3 years.
  • Recent therapeutic advancements have transformed the treatment landscape for multiple myeloma patients.

Purpose of the Study:

  • To review recent breakthroughs in multiple myeloma management.
  • To offer an evidence-based treatment approach for multiple myeloma.

Main Methods:

  • Review of recent clinical advances in multiple myeloma therapy.
  • Evidence-based analysis of novel treatment modalities and supportive care.

Main Results:

  • Autologous stem cell transplantation is now a standard initial therapy for newly diagnosed patients with good performance status, improving survival.

Related Experiment Videos

  • Thalidomide has shown significant activity in refractory myeloma, leading to the investigation of other novel agents.
  • Supportive care, including bisphosphonates for osteolytic lesions, has also seen improvement.

    • Conclusions:

    • Current treatment strategies for multiple myeloma have evolved significantly, offering improved outcomes.
    • Ongoing research into novel agents and transplantation protocols continues to advance care for multiple myeloma patients.